Compile Data Set for Download or QSAR
Report error Found 21 Enz. Inhib. hit(s) with all data for entry = 10508
TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM542482(US11274095, Example 14-Enantiomer-2 | US11274095, ...)
Affinity DataIC50: 0.0370nMAssay Description:EZH2 biochemical assay (IC50): Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/4/2022
Entry Details
US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM542469(US11274095, Example 4)
Affinity DataIC50: 0.0380nMAssay Description:EZH2 biochemical assay (IC50): Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/4/2022
Entry Details
US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM542475(7-chloro-N-((4-chloro-6-methyl-2-oxo-1,2-dihydropy...)
Affinity DataIC50: 0.0390nMAssay Description:EZH2 biochemical assay (IC50): Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/4/2022
Entry Details
US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM542486(7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-...)
Affinity DataIC50: 0.0430nMAssay Description:EZH2 biochemical assay (IC50): Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/4/2022
Entry Details
US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM542470(US11274095, Example 5)
Affinity DataIC50: 0.0540nMAssay Description:EZH2 biochemical assay (IC50): Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/4/2022
Entry Details
US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM542476(US11274095, Example 9)
Affinity DataIC50: 0.0540nMAssay Description:EZH2 biochemical assay (IC50): Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/4/2022
Entry Details
US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM542481(US11274095, Example 13)
Affinity DataIC50: 0.0840nMAssay Description:EZH2 biochemical assay (IC50): Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/4/2022
Entry Details
US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM542466(US11274095, Example 1)
Affinity DataIC50: 0.0910nMAssay Description:EZH2 biochemical assay (IC50): Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/4/2022
Entry Details
US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM542480(US11274095, Example 12)
Affinity DataIC50: 0.0920nMAssay Description:EZH2 biochemical assay (IC50): Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/4/2022
Entry Details
US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM542473(US11274095, Example 7-Enantiomer-2 | US11274095, E...)
Affinity DataIC50: 0.120nMAssay Description:EZH2 biochemical assay (IC50): Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/4/2022
Entry Details
US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM542478(US11274095, Example 11-isomer-2 | US11274095, Exam...)
Affinity DataIC50: 0.140nMAssay Description:EZH2 biochemical assay (IC50): Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/4/2022
Entry Details
US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM542471(US11274095, Example 6-Enantiomer-2 | US11274095, E...)
Affinity DataIC50: 0.140nMAssay Description:EZH2 biochemical assay (IC50): Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/4/2022
Entry Details
US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM542478(US11274095, Example 11-isomer-2 | US11274095, Exam...)
Affinity DataIC50: 0.180nMAssay Description:EZH2 biochemical assay (IC50): Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/4/2022
Entry Details
US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM542477(US11274095, Example 10)
Affinity DataIC50: 0.202nMAssay Description:EZH2 biochemical assay (IC50): Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/4/2022
Entry Details
US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM542484(US11274095, Example 16-Enantiomer-1 | US11274095, ...)
Affinity DataIC50: 0.310nMAssay Description:EZH2 biochemical assay (IC50): Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/4/2022
Entry Details
US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM542468(US11274095, Example 3)
Affinity DataIC50: 0.370nMAssay Description:EZH2 biochemical assay (IC50): Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/4/2022
Entry Details
US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM542467(US11274095, Example 2)
Affinity DataIC50: 1.5nMAssay Description:EZH2 biochemical assay (IC50): Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/4/2022
Entry Details
US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM542471(US11274095, Example 6-Enantiomer-2 | US11274095, E...)
Affinity DataIC50: 1.80nMAssay Description:EZH2 biochemical assay (IC50): Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/4/2022
Entry Details
US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM542482(US11274095, Example 14-Enantiomer-2 | US11274095, ...)
Affinity DataIC50: 7nMAssay Description:EZH2 biochemical assay (IC50): Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/4/2022
Entry Details
US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM542473(US11274095, Example 7-Enantiomer-2 | US11274095, E...)
Affinity DataIC50: 8.60nMAssay Description:EZH2 biochemical assay (IC50): Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/4/2022
Entry Details
US Patent

TargetHistone-lysine N-methyltransferase EZH2(Human)
Constellation Pharmaceuticals

US Patent
LigandPNGBDBM542484(US11274095, Example 16-Enantiomer-1 | US11274095, ...)
Affinity DataIC50: 10nMAssay Description:EZH2 biochemical assay (IC50): Compound potencies were assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, 30 pM P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/4/2022
Entry Details
US Patent